Search research articles
Contact Us
Filters
Showing results (11-20 of 136) with videos related to
Page
of 14
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
December 9, 2016
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia
Marco L Davila, Renier J Brentjens
Biochemical Society Transactions
|
April 13, 2016
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy
Oladapo O Yeku, Renier J Brentjens
American Journal of Hematology
|
January 26, 2019
CARs of the future
Anthony F Daniyan, Renier J Brentjens
Journal of Lipid Mediators
|
March 1, 1991
Receptor antagonists of platelet-activating factor do not influence the development of passive Heymann nephritis
G Salvidio, J Brentjens, G Camussi
Hematology. American Society of Hematology. Education Program
|
December 13, 2012
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen
Renier J Brentjens, Kevin J Curran
Discovery Medicine
|
January 28, 2010
Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer
Alena A Chekmasova, Renier J Brentjens
Discovery Medicine
|
April 29, 2010
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells
Jae H Park, Renier J Brentjens
Cytotherapy
|
September 5, 2016
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
Mark B Geyer, Renier J Brentjens
Advances in Experimental Medicine and Biology
|
September 10, 2013
Immunotherapies in CLL
Jae H Park, Renier J Brentjens
American Journal of Otolaryngology
|
January 1, 1982
Are immune complexes a factor in the pathogenesis of otitis media with effusion?
J M Bernstein, J Brentjens, A Vladutiu
Page
of 14
Search research articles
Search
Showing results (11-20 of 136) with videos related to
Sort By:
Page
of 14
Clinical Advances in Hematology & Oncology : H&O
|
December 9, 2016
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia
Marco L Davila, Renier J Brentjens
Biochemical Society Transactions
|
April 13, 2016
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy
Oladapo O Yeku, Renier J Brentjens
American Journal of Hematology
|
January 26, 2019
CARs of the future
Anthony F Daniyan, Renier J Brentjens
Journal of Lipid Mediators
|
March 1, 1991
Receptor antagonists of platelet-activating factor do not influence the development of passive Heymann nephritis
G Salvidio, J Brentjens, G Camussi
Hematology. American Society of Hematology. Education Program
|
December 13, 2012
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen
Renier J Brentjens, Kevin J Curran
Discovery Medicine
|
January 28, 2010
Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer
Alena A Chekmasova, Renier J Brentjens
Discovery Medicine
|
April 29, 2010
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells
Jae H Park, Renier J Brentjens
Cytotherapy
|
September 5, 2016
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
Mark B Geyer, Renier J Brentjens
Advances in Experimental Medicine and Biology
|
September 10, 2013
Immunotherapies in CLL
Jae H Park, Renier J Brentjens
American Journal of Otolaryngology
|
January 1, 1982
Are immune complexes a factor in the pathogenesis of otitis media with effusion?
J M Bernstein, J Brentjens, A Vladutiu
Page
of 14